B A C K G R O U N D Description of the condition
Asthma is a chronic inflammatory condition of the airways, characterised by recurrent attacks of breathlessness, wheezing, cough and chest tightness, termed 'exacerbations'. The prevalence of asthma varies widely between countries. In children, the prevalence of severe asthma symptoms ranges from 0% (India) to 20.3% (Costa Rica) (Lai 2009); in adults, the prevalence of doctor-diagnosed asthma ranges from 0.2% (China) to 21.0% (Australia) (To 2012). Exacerbations represent the major cause of morbidity and mortality in patients with asthma (Johnston 2006). Asthma exacerbations are classified as severe when they result in hospitalisation or death, and moderate when they prompt a need for a change in treatment, such as initiation of systemic corticosteroids, without causing death or hospitalisation (Reddel 2009). Common precipitants of asthma exacerbation include acute respiratory infections and exposure to allergens and particulates (Singh 2006) .
Description of the intervention
Vitamin D is a pre-pro-hormone that has two parent forms: cholecalciferol (vitamin D 3 ) and ergocalciferol (vitamin D 2 ). Cholecalciferol is synthesised in human skin from its precursor molecule 7-dehydrocholesterol on exposure to ultraviolet B (UVB) radiation in sunlight; it may also be ingested, either in the diet (primarily from eating oily fish) or in vitamin D supplements. Ergocalciferol is the plant and fungal form of the vitamin, which may occasionally be ingested in the diet (primarily by eating fungi) or in vitamin D supplements. In situations where cutaneous exposure to UVB radiation of appropriate intensity is limited (e.g. during winter at latitudes above 34ºN or below 34ºS, or in settings where people do not regularly expose their skin to sunlight), dietary sources of . This 1-alpha hydroxylation step is catalysed by the enzyme CYP27B1, which is expressed in multiple tissues including the kidney, leucocytes and pulmonary epithelium; expression of CYP27B1 in leucocytes and pulmonary epithelium is up-regulated in response to infection and inflammation. This review will include studies which evaluate the effects of administration, by any route and at any dose, of vitamin D 3 , vitamin 
Why it is important to do this review
There is considerable interest in the potential of administration of vitamin D to reduce exacerbation risk and improve asthma symptom control. Two small trials of vitamin D supplementation in children with asthma treated with inhaled corticosteroids have reported reduced rates of exacerbation among participants randomised to the intervention arm (Majak 2011; Yadav 2014), and one small trial showed no effect of vitamin D supplementation on inflammatory markers or lung function (Bar Yoseph 2014). One larger trial in adults has also reported a trend towards reduced exacerbation rate in the intervention arm (adjusted Hazard Ratio 0.63, 95% confidence interval (CI) 0.39 to 1.01) (Castro 2014). Other trials are either in progress or completed but as yet unpublished. Meta-analysis of these trials has the potential to increase statistical power to detect effects of administering vitamin D on exacerbation risk and symptom control both in study populations as a whole, and within subgroups who might be expected to derive particular benefit from this intervention (e.g. those with lower vitamin D status at enrolment).
O B J E C T I V E S
To evaluate the efficacy of administration of vitamin D and its hydroxylated metabolites in reducing asthma exacerbations and improving asthma symptom control.
M E T H O D S Criteria for considering studies for this review Types of studies
We will review double-blind randomised placebo-controlled trials of at least twelve weeks' duration. We will include studies reported as full-text and unpublished data. Studies published as abstract only will also be included, but we will note that they are pending definitive evaluation as and when fuller reports are available.
Types of participants
We will include children and adults with a clinical diagnosis of asthma, based on the presence of characteristic symptoms and variable airflow obstruction. No restrictions regarding disease severity, baseline vitamin D status or duration of treatment with asthma medication will be imposed, in order to maximise generalisability.
Types of interventions
We will include studies in which vitamin D 3 , vitamin D 2 , 25(OH)D or 1,25(OH) 2 D are administered at any dose.
Types of outcome measures Primary outcomes
The primary outcome of this review is asthma exacerbation treated with systemic corticosteroids. 
Search methods for identification of studies Electronic searches
We will identify trials from the Cochrane Airways Group's Specialised Register (CAGR), which is maintained by the Trials Search Co-ordinator for the Group. The Register contains trial reports identified through systematic searches of bibliographic databases including the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, CINAHL, AMED, and PsycINFO, and handsearching of respiratory journals and meeting abstracts (please see Appendix 1 for further details). We will search all records in the CAGR using the search strategy in Appendix 2. We will also conduct searches of ClinicalTrials.gov (www.ClinicalTrials.gov), the WHO trials portal (www.who.int/ictrp/en/), the ISRCTN clinical trials register (http://www.controlled-trials.com/isrctn/ ), the Australian New Zealand Clinical Trials Registry (http://www.anzctr.org.au/ ) and the UMIN Clinical Trials Registry (http://www.umin.ac.jp/ctr/). We will search all databases from their inception to the present, and we will impose no restriction on language of publication.
Searching other resources
We will check reference lists of all primary studies and review articles for additional references. We will search relevant manufacturers' websites for trial information. We will search for errata or retractions from included studies published in full-text on PubMed (www.ncbi.nlm.nih.gov/pubmed) and report the date this was done within the review. We will contact a panel of international experts for additional references and information on trials in progress.
Data collection and analysis

Selection of studies
Two review authors (ARM, AT) will independently screen for inclusion the titles and abstracts of all the potentially relevant studies we identify as a result of the search, and code them as 'retrieve' (eligible or potentially eligible/unclear) or 'do not retrieve'. We will retrieve the full-text study reports/publication and two review authors (ARM, AT) will independently screen the full-text and identify studies for inclusion, and identify and record reasons for exclusion of the ineligible studies. We will resolve any disagreement through discussion or, if required, we will consult a third person (CJG or AS). We will identify and exclude duplicates and collate multiple reports of the same study so that each study rather than each report is the unit of interest in the review. We will record the selection process in sufficient detail to complete a PRISMA flow diagram and 'Characteristics of excluded studies' table (Moher 2009).
Data extraction and management
We will use a data collection form for study characteristics and outcome data, which has been piloted on at least one study in the review. Two review authors (ARM, AT) will extract study characteristics from included studies. We will extract the following study characteristics.
1. Methods: study design, total duration of study, details of any 'run-in' period, number of study centres and location, study setting, withdrawals, and date of study.
2. Participants: N, mean age, age range, gender, body mass index, severity of condition, diagnostic criteria, baseline lung function, smoking history, inclusion criteria, and exclusion criteria.
3. Interventions: intervention, comparison, concomitant medications, and excluded medications.
4. Outcomes: primary and secondary outcomes specified and collected, and time points reported. 5. Notes: funding for trial, and notable conflicts of interest of trial authors.
Two review authors (ARM, AT) will independently extract outcome data from included studies. We will note in the 'Characteristics of included studies' table if outcome data were not reported in a usable way. We will resolve disagreements by consensus or by involving a third person (CJG or AS). One review author (AT) will transfer data into the RevMan 2014 file. We will double-check that data are entered correctly by comparing the data presented in the systematic review with the study reports. A second review author (ARM) will spot-check study characteristics for accuracy against the trial reports.
Assessment of risk of bias in included studies
Two review authors (TBA, AT) will independently assess the risk of bias for each study using the criteria outlined in the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2011). We will resolve any disagreements by discussion or by involving another author (CJG or AS). We will assess the risk of bias according to the following domains.
1. Random sequence generation; 2. Allocation concealment; 3. Blinding of participants and personnel; 4. Blinding of outcome assessment; 5. Incomplete outcome data; 6. Selective outcome reporting; 7. Other biases, including study size We will grade each potential source of bias as high, low or unclear and provide a quote from the study report together with a justification for our judgment in the 'Risk of bias' table. We will summarise the 'Risk of bias' judgements across different studies for each of the domains listed. We will consider blinding separately for different key outcomes where necessary (e.g. for unblinded outcome assessment, risk of bias for all-cause mortality may be very different than for a patient-reported pain scale). Where information on risk of bias relates to unpublished data or correspondence with a trialist, we will note this in the 'Risk of bias' table. When considering treatment effects, we will take into account the risk of bias for the studies that contribute to that outcome.
Assesment of bias in conducting the systematic review
We will conduct the review according to this published protocol and report any deviations from it in the 'Differences between protocol and review' section of the systematic review.
Measures of treatment effect
We will analyse dichotomous data as odds ratios, since the rate of exacerbations may vary widely between studies, and the weights for each study using relative risk will be heavily dependent on the choice of outcome measure. We will analyse continuous data as mean difference or standardised mean difference. We will enter data presented as a scale with a consistent direction of effect. We will undertake meta-analyses only where this is meaningful i.e. if the treatments, participants and the underlying clinical question are similar enough for pooling to make sense. We will narratively describe skewed data reported as medians and interquartile ranges. Where multiple trial arms are reported in a single trial, we will include only the relevant arms. If two comparisons (e.g. drug A versus placebo and drug B versus placebo) are combined in the same meta-analysis, we will halve the control group to avoid double-counting. For outcomes measured at different time points, we will include the longest time point after randomisation.
Unit of analysis issues
Where data are expressed in unconventional units of analysis we will convert them to conventional units, liaising with authors if required.
Dealing with missing data
We will contact investigators or study sponsors in order to verify key study characteristics and obtain missing numerical outcome data where possible (e.g. when a study is identified as abstract only). Where this is not possible, and the missing data are thought to introduce serious bias, we will explore the impact of including such studies in the overall assessment of results by a sensitivity analysis.
Assessment of heterogeneity
We will use the I² statistic to measure heterogeneity among the trials in each analysis. If we identify substantial heterogeneity (I 2 > 40%) we will report it and explore possible causes by pre-specified subgroup analysis.
Assessment of reporting biases
If we are able to pool more than 10 trials, we will create and examine a funnel plot to explore possible small study biases.
Data synthesis
We expect significant heterogeneity: accordingly, we will use a random-effects model and perform a sensitivity analysis with a fixed-effect model. An intention-to-treat model will be used to analyse data when possible. Continuous data will be analysed as a mean difference; dichotomous data will be reported as odds ratios. Number needed to treat for an additional beneficial outcome (NNTB) and number needed to treat for an additional harmful outcome (NNTH) for adverse events will be calculated where appropriate, to give an indication for each dichotomous outcome, to reflect the number of patients required to achieve a benefit or disbenefit with the intervention. Means and standard deviations (SDs) will be used when available. We will approach authors where data are not reported. Values will be extracted from graphs if authors do not respond.
'Summary of findings' table
We will create a 'Summary of findings' table using the following outcomes: incidence of moderate/severe asthma exacerbation; proportion of patients with one or more emergency department attendance or hospitalisation for asthma; asthma symptom control; asthma quality of life; lung function; biomarkers of asthma control; and incidence of severe adverse events attributed to administration of vitamin D. We will use the five GRADE considerations (study limitations, consistency of effect, imprecision, indirectness and publication bias) to assess the quality of a body of evidence as it relates to the studies which contribute data to the meta-analyses for the pre-specified outcomes. We will use methods and recommendations described in Section 8.5 and Chapter 12 of the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2011) using GRADEpro software. We will calculate NNTB from the control group event rate (unless the population event rate is known) and odds ratios using the Visual Rx NNT calculator (http://www.nntonline.net/visualrx/). We will list trials in progress. We will justify all decisions to down-or up-grade the quality of studies using footnotes and we will make comments to aid readers' understanding of the review where necessary.
Subgroup analysis and investigation of heterogeneity
We plan to carry out the following subgroup analyses. 5. The frequency of administration (e.g. daily versus intermittent bolus doses);
6. Genetic variation in pathways of vitamin D metabolism, transport and signalling (e.g. GC 2/2 versus 2/1 versus 1/1
